U.S. Cell Therapy Manufacturing Market Size to Hit USD 6.56 Billion by 2035

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Cell Therapy Manufacturing Market

5.1. COVID-19 Landscape: Cell Therapy Manufacturing Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. U.S. Cell Therapy Manufacturing Market, By Therapy Type

8.1. U.S. Cell Therapy Manufacturing Market, by Therapy Type

8.1.1. Allogenic Cell Therapy

8.1.1.1. Market Revenue and Forecast

8.1.2. Autologous Cell Therapy

8.1.2.1. Market Revenue and Forecast

Chapter 9. U.S. Cell Therapy Manufacturing Market, By Technology Type

9.1. U.S. Cell Therapy Manufacturing Market, by Technology Type

9.1.1. Somatic Cell Technology

9.1.1.1. Market Revenue and Forecast

9.1.2. Cell Immortalization Technology

9.1.2.1. Market Revenue and Forecast

9.1.3. Viral Vector Technology

9.1.3.1. Market Revenue and Forecast

9.1.4. Genome Editing Technology

9.1.4.1. Market Revenue and Forecast

9.1.5. Cell Plasticity Technology

9.1.5.1. Market Revenue and Forecast

9.1.6. 3D Technology

9.1.6.1. Market Revenue and Forecast

Chapter 10. U.S. Cell Therapy Manufacturing Market, By Source

10.1. U.S. Cell Therapy Manufacturing Market, by Source

10.1.1. IPSC (Induced Pluripotent Stem Cell)

10.1.1.1. Market Revenue and Forecast

10.1.2. Bone Marrow

10.1.2.1. Market Revenue and Forecast

10.1.3. Umbilical Cord

10.1.3.1. Market Revenue and Forecast

10.1.4. Adipose Tissues

10.1.4.1. Market Revenue and Forecast

10.1.5. Neural Stem

10.1.5.1. Market Revenue and Forecast

Chapter 11. U.S. Cell Therapy Manufacturing Market, By Application

11.1. U.S. Cell Therapy Manufacturing Market, by Application

11.1.1. Musculoskeletal

11.1.1.1. Market Revenue and Forecast

11.1.2. Cardiovascular

11.1.2.1. Market Revenue and Forecast

11.1.3. Gastrointestinal

11.1.3.1. Market Revenue and Forecast

11.1.4. Neurological

11.1.4.1. Market Revenue and Forecast

11.1.5. Oncology

11.1.5.1. Market Revenue and Forecast

11.1.6. Dermatology

11.1.6.1. Market Revenue and Forecast

11.1.7. Others

11.1.7.1. Market Revenue and Forecast

Chapter 12. U.S. Cell Therapy Manufacturing Market, Regional Estimates and Trend Forecast

12.1.5. U.S.

12.1.5.1. Market Revenue and Forecast, by Therapy Type

12.1.5.2. Market Revenue and Forecast, by Technology Type

12.1.5.3. Market Revenue and Forecast, by Source

12.1.5.4. Market Revenue and Forecast, by Application

Chapter 13. Company Profiles

13.1. Abbott

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. Thermo Fisher Scientific

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. Catalent, Inc

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. Bio-Techne

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. Cytiva

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. Lonza

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. The Discovery Labs

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. Novartis AG

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. Bristol-Myers Squibb Company

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

13.10. Gilead Sciences, Inc.

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial Performance

13.10.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

Answer : The U.S. cell therapy manufacturing market size is expected to increase from USD 1.71 billion in 2025 to USD 6.56 billion by 2035.

Answer : The U.S. cell therapy manufacturing market is expected to grow at a compound annual growth rate (CAGR) of around 14.39% from 2026 to 2035.

Answer : The major players in the U.S. cell therapy manufacturing market include Merck KGaA, Thermo Fisher Scientific, Catalent, Inc, Bio-Techne, Novartis AG, Bristol-Myers Squibb Company, Gilead Sciences, Inc., Cytiva, Lonza, and The Discovery Labs.

Answer : The driving factors of the U.S. cell therapy manufacturing market are the increasing clinical development and commercialization of cell-based therapies, rising investments in biopharmaceutical manufacturing infrastructure, and growing demand for scalable, automated production technologies.